
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="67D7125089B71C131C1250000B86D17D.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333328/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Hematological Oncology">
<meta name="citation_title" content="Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study">
<meta name="citation_author" content="Alessandra Iurlo">
<meta name="citation_author_institution" content="Hematology Division, Foundation IRCCS Ca&#x27; Granda Ospedale Maggiore Policlinico, Milan, Italy">
<meta name="citation_author" content="Massimo Breccia">
<meta name="citation_author_institution" content="Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, Rome, Italy">
<meta name="citation_author" content="Fabio Stagno">
<meta name="citation_author_institution" content="Hematology Unit, AOU Policlinico “G. Martino”, University of Messina, Messina, Italy">
<meta name="citation_author" content="Elisabetta Abruzzese">
<meta name="citation_author_institution" content="Hematology, S. Eugenio Hospital, Tor Vergata University, ASL Roma 2, Rome, Italy">
<meta name="citation_author" content="Fabrizio Pane">
<meta name="citation_author_institution" content="Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy">
<meta name="citation_author" content="Immacolata Attolico">
<meta name="citation_author_institution" content="Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari, Hematology Section, Bari, Italy">
<meta name="citation_author" content="Paolo Sportoletti">
<meta name="citation_author_institution" content="Centro di Ricerca Emato‐Oncologica (CREO), University of Perugia, Perugia, Italy">
<meta name="citation_author" content="Marco Cerrano">
<meta name="citation_author_institution" content="Hematology Unit, Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza, Turin, Italy">
<meta name="citation_author" content="Sara Galimberti">
<meta name="citation_author_institution" content="Department of Clinical and Experimental Medicine, Hematology Section, University of Pisa, Pisa, Italy">
<meta name="citation_author" content="Barbara Scappini">
<meta name="citation_author_institution" content="Hematology, AOU Careggi, University of Florence, Florence, Italy">
<meta name="citation_author" content="Maurizio Miglino">
<meta name="citation_author_institution" content="Hematology Clinic, IRCCS San Martino Hospital, Genoa, Italy">
<meta name="citation_author" content="Sergio Siragusa">
<meta name="citation_author_institution" content="Pro.Mi.Se Department, University of Palermo, Palermo, Italy">
<meta name="citation_author" content="Isabella Capodanno">
<meta name="citation_author_institution" content="Hematology Department, Azienda Unità Sanitaria Locale‐IRCCS di Reggio Emilia, Reggio Emilia, Italy">
<meta name="citation_author" content="Diletta Valsecchi">
<meta name="citation_author_institution" content="Novartis Farma SpA, Milan, Italy">
<meta name="citation_author" content="Aurelio Pio Nardozza">
<meta name="citation_author_institution" content="Novartis Farma SpA, Milan, Italy">
<meta name="citation_author" content="Alessandra Misto">
<meta name="citation_author_institution" content="Novartis Farma SpA, Milan, Italy">
<meta name="citation_author" content="Paola Coco">
<meta name="citation_author_institution" content="Novartis Farma SpA, Milan, Italy">
<meta name="citation_author" content="Giuseppe Saglio">
<meta name="citation_author_institution" content="Department of Clinical and Biological Sciences, University of Turin, Turin, Italy">
<meta name="citation_author" content="Gianantonio Rosti">
<meta name="citation_author_institution" content="IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy">
<meta name="citation_publication_date" content="2025 Aug 8">
<meta name="citation_volume" content="43">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="e70126">
<meta name="citation_doi" content="10.1002/hon.70126">
<meta name="citation_pmid" content="40778574">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333328/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333328/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333328/pdf/HON-43-e70126.pdf">
<meta name="description" content="Treatment‐free remission (TFR) in chronic myeloid leukemia (CML) can be considered for patients in sustained deep molecular response (DMR) who can discontinue tyrosine kinase inhibitors (TKIs) while maintaining responses. Studies suggest that TKI ...">
<meta name="og:title" content="Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Treatment‐free remission (TFR) in chronic myeloid leukemia (CML) can be considered for patients in sustained deep molecular response (DMR) who can discontinue tyrosine kinase inhibitors (TKIs) while maintaining responses. Studies suggest that TKI ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333328/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12333328">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/hon.70126"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/HON-43-e70126.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12333328%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12333328/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12333328/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333328/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/hon.70126" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Hematol Oncol</button></div>. 2025 Aug 8;43(5):e70126. doi: <a href="https://doi.org/10.1002/hon.70126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/hon.70126</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hematol%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Hematol%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Iurlo%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Alessandra Iurlo</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Alessandra Iurlo</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Iurlo%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessandra Iurlo</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Breccia%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Massimo Breccia</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Massimo Breccia</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, Rome, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Breccia%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Massimo Breccia</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stagno%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Fabio Stagno</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Fabio Stagno</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Hematology Unit, AOU Policlinico “G. Martino”, University of Messina, Messina, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stagno%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fabio Stagno</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abruzzese%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Elisabetta Abruzzese</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Elisabetta Abruzzese</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Hematology, S. Eugenio Hospital, Tor Vergata University, ASL Roma 2, Rome, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abruzzese%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Elisabetta Abruzzese</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pane%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Fabrizio Pane</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Fabrizio Pane</span></h3>
<div class="p">
<sup>
<sup>5</sup>
</sup>Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pane%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fabrizio Pane</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Attolico%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Immacolata Attolico</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Immacolata Attolico</span></h3>
<div class="p">
<sup>
<sup>6</sup>
</sup>Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari, Hematology Section, Bari, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Attolico%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Immacolata Attolico</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sportoletti%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Paolo Sportoletti</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Paolo Sportoletti</span></h3>
<div class="p">
<sup>
<sup>7</sup>
</sup>Centro di Ricerca Emato‐Oncologica (CREO), University of Perugia, Perugia, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sportoletti%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Paolo Sportoletti</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cerrano%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Marco Cerrano</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Marco Cerrano</span></h3>
<div class="p">
<sup>
<sup>8</sup>
</sup>Hematology Unit, Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza, Turin, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cerrano%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marco Cerrano</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Galimberti%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Sara Galimberti</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Sara Galimberti</span></h3>
<div class="p">
<sup>
<sup>9</sup>
</sup>Department of Clinical and Experimental Medicine, Hematology Section, University of Pisa, Pisa, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Galimberti%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sara Galimberti</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Scappini%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Barbara Scappini</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Barbara Scappini</span></h3>
<div class="p">
<sup>
<sup>10</sup>
</sup>Hematology, AOU Careggi, University of Florence, Florence, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Scappini%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Barbara Scappini</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Miglino%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Maurizio Miglino</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Maurizio Miglino</span></h3>
<div class="p">
<sup>
<sup>11</sup>
</sup>Hematology Clinic, IRCCS San Martino Hospital, Genoa, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Miglino%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maurizio Miglino</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Siragusa%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Sergio Siragusa</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Sergio Siragusa</span></h3>
<div class="p">
<sup>
<sup>12</sup>
</sup>Pro.Mi.Se Department, University of Palermo, Palermo, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Siragusa%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sergio Siragusa</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Capodanno%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Isabella Capodanno</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Isabella Capodanno</span></h3>
<div class="p">
<sup>
<sup>13</sup>
</sup>Hematology Department, Azienda Unità Sanitaria Locale‐IRCCS di Reggio Emilia, Reggio Emilia, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Capodanno%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Isabella Capodanno</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Valsecchi%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Diletta Valsecchi</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Diletta Valsecchi</span></h3>
<div class="p">
<sup>
<sup>14</sup>
</sup>Novartis Farma SpA, Milan, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Valsecchi%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Diletta Valsecchi</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nardozza%20AP%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Aurelio Pio Nardozza</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Aurelio Pio Nardozza</span></h3>
<div class="p">
<sup>
<sup>14</sup>
</sup>Novartis Farma SpA, Milan, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nardozza%20AP%22%5BAuthor%5D" class="usa-link"><span class="name western">Aurelio Pio Nardozza</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Misto%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Alessandra Misto</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Alessandra Misto</span></h3>
<div class="p">
<sup>
<sup>14</sup>
</sup>Novartis Farma SpA, Milan, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Misto%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessandra Misto</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Coco%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Paola Coco</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Paola Coco</span></h3>
<div class="p">
<sup>
<sup>14</sup>
</sup>Novartis Farma SpA, Milan, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Coco%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Paola Coco</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Saglio%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Giuseppe Saglio</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Giuseppe Saglio</span></h3>
<div class="p">
<sup>
<sup>15</sup>
</sup>Department of Clinical and Biological Sciences, University of Turin, Turin, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Saglio%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giuseppe Saglio</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rosti%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Gianantonio Rosti</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Gianantonio Rosti</span></h3>
<div class="p">
<sup>
<sup>16</sup>
</sup>IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rosti%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gianantonio Rosti</span></a>
</div>
</div>
<sup>16</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="hon70126-aff-0001">
<sup>
<sup>1</sup>
</sup>Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy</div>
<div id="hon70126-aff-0002">
<sup>
<sup>2</sup>
</sup>Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, Rome, Italy</div>
<div id="hon70126-aff-0003">
<sup>
<sup>3</sup>
</sup>Hematology Unit, AOU Policlinico “G. Martino”, University of Messina, Messina, Italy</div>
<div id="hon70126-aff-0004">
<sup>
<sup>4</sup>
</sup>Hematology, S. Eugenio Hospital, Tor Vergata University, ASL Roma 2, Rome, Italy</div>
<div id="hon70126-aff-0005">
<sup>
<sup>5</sup>
</sup>Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy</div>
<div id="hon70126-aff-0006">
<sup>
<sup>6</sup>
</sup>Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari, Hematology Section, Bari, Italy</div>
<div id="hon70126-aff-0007">
<sup>
<sup>7</sup>
</sup>Centro di Ricerca Emato‐Oncologica (CREO), University of Perugia, Perugia, Italy</div>
<div id="hon70126-aff-0008">
<sup>
<sup>8</sup>
</sup>Hematology Unit, Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza, Turin, Italy</div>
<div id="hon70126-aff-0009">
<sup>
<sup>9</sup>
</sup>Department of Clinical and Experimental Medicine, Hematology Section, University of Pisa, Pisa, Italy</div>
<div id="hon70126-aff-0010">
<sup>
<sup>10</sup>
</sup>Hematology, AOU Careggi, University of Florence, Florence, Italy</div>
<div id="hon70126-aff-0011">
<sup>
<sup>11</sup>
</sup>Hematology Clinic, IRCCS San Martino Hospital, Genoa, Italy</div>
<div id="hon70126-aff-0012">
<sup>
<sup>12</sup>
</sup>Pro.Mi.Se Department, University of Palermo, Palermo, Italy</div>
<div id="hon70126-aff-0013">
<sup>
<sup>13</sup>
</sup>Hematology Department, Azienda Unità Sanitaria Locale‐IRCCS di Reggio Emilia, Reggio Emilia, Italy</div>
<div id="hon70126-aff-0014">
<sup>
<sup>14</sup>
</sup>Novartis Farma SpA, Milan, Italy</div>
<div id="hon70126-aff-0015">
<sup>
<sup>15</sup>
</sup>Department of Clinical and Biological Sciences, University of Turin, Turin, Italy</div>
<div id="hon70126-aff-0016">
<sup>
<sup>16</sup>
</sup>IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong> Alessandra Iurlo, 
(<span>alessandra.iurlo@policlinico.mi.it</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 18; Received 2025 Mar 24; Accepted 2025 Aug 3; Issue date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Hematological Oncology</em> published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12333328  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40778574/" class="usa-link">40778574</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Treatment‐free remission (TFR) in chronic myeloid leukemia (CML) can be considered for patients in sustained deep molecular response (DMR) who can discontinue tyrosine kinase inhibitors (TKIs) while maintaining responses. Studies suggest that TKI de‐escalation before TFR is feasible. This phase II study evaluated nilotinib de‐escalation outcomes in adults with CML in chronic phase (CP) treated with first‐line nilotinib for ≥ 3 years and in sustained DMR for ≥ 1 year. The study had four phases: screening, de‐escalation (week 0–48), TFR (week 48–144) and follow‐up. During de‐escalation, patients received nilotinib 300 mg once daily, and those with sustained DMR entered TFR and discontinued nilotinib. Patients with major molecular response (MMR) but without sustained DMR continued nilotinib. At the data cut‐off, 107 patients entered, and 98 (91.6%) completed de‐escalation. TFR was entered by 90 patients (84.1%) with sustained DMR. At 96 weeks, 71/107 patients (66.4%) were in full TFR; 64/90 patients (71.1%) who entered TFR remained in ≥ MMR, and the median time‐to‐loss of MMR was not reached. During TFR, adverse events occurred in 64 patients (71.1%), including one serious event (pneumonia). Our data suggest that the de‐escalation of nilotinib before a TFR attempt in CML‐CP patients with sustained DMR can be a successful dose optimization strategy.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> chronic myeloid leukemia, nilotinib, sustained deep molecular response, treatment‐free remission</p></section></section><section id="hon70126-sec-0010"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Chronic myeloid leukemia (CML) is characterized by the presence of the <em>BCR::ABL1</em> fusion gene on the Philadelphia chromosome [<a href="#hon70126-bib-0001" class="usa-link" aria-describedby="hon70126-bib-0001">1</a>]. This gene produces the BCR::ABL1 tyrosine kinase, which results in leukemia cell proliferation [<a href="#hon70126-bib-0002" class="usa-link" aria-describedby="hon70126-bib-0002">2</a>]. CML usually presents in chronic phase (CP), in which the clonal expansion of mature myeloid cells leads to an elevated white blood cell count [<a href="#hon70126-bib-0003" class="usa-link" aria-describedby="hon70126-bib-0003">3</a>]. The annual incidence of CML ranges from 0.4 to 1.75/100,000, and the median age at diagnosis is 57–60 years [<a href="#hon70126-bib-0004" class="usa-link" aria-describedby="hon70126-bib-0004">4</a>]. The prevalence of CML is estimated to be 10–12/100,000 and is increasing due to considerable improvements in patient survival [<a href="#hon70126-bib-0004" class="usa-link" aria-describedby="hon70126-bib-0004">4</a>].</p>
<p>The optimal front‐line treatment for patients with CML‐CP is the subject of active clinical evaluation but involves <em>BCR::ABL1</em> tyrosine kinase inhibitors (TKIs), namely imatinib, nilotinib, dasatinib, and bosutinib [<a href="#hon70126-bib-0005" class="usa-link" aria-describedby="hon70126-bib-0005">5</a>]. Outcomes for patients with CML have vastly improved with the introduction of TKIs, with life expectancy reaching that of healthy age‐matched individuals [<a href="#hon70126-bib-0006" class="usa-link" aria-describedby="hon70126-bib-0006">6</a>]. However, the adverse effects and costs associated with lifelong TKI treatment considerably affect patients' quality of life, ultimately impacting treatment adherence and response [<a href="#hon70126-bib-0007" class="usa-link" aria-describedby="hon70126-bib-0007">7</a>, <a href="#hon70126-bib-0008" class="usa-link" aria-describedby="hon70126-bib-0008">8</a>, <a href="#hon70126-bib-0009" class="usa-link" aria-describedby="hon70126-bib-0009">9</a>, <a href="#hon70126-bib-0010" class="usa-link" aria-describedby="hon70126-bib-0010">10</a>].</p>
<p>This has led to a focus on whether it is possible to discontinue treatment in certain patients to mitigate adverse effects and financial burdens [<a href="#hon70126-bib-0011" class="usa-link" aria-describedby="hon70126-bib-0011">11</a>]. Furthermore, female patients who are pregnant or planning to become pregnant may benefit from stopping TKIs to reduce the risk of teratogenic effects [<a href="#hon70126-bib-0012" class="usa-link" aria-describedby="hon70126-bib-0012">12</a>]. Because of the success of TKIs, treatment discontinuation became a new goal of therapeutic projects: indeed, many studies have shown that 40%–70% of patients with sustained deep molecular response (DMR) can safely discontinue TKIs without hematological relapse [<a href="#hon70126-bib-0013" class="usa-link" aria-describedby="hon70126-bib-0013">13</a>, <a href="#hon70126-bib-0014" class="usa-link" aria-describedby="hon70126-bib-0014">14</a>, <a href="#hon70126-bib-0015" class="usa-link" aria-describedby="hon70126-bib-0015">15</a>, <a href="#hon70126-bib-0016" class="usa-link" aria-describedby="hon70126-bib-0016">16</a>, <a href="#hon70126-bib-0017" class="usa-link" aria-describedby="hon70126-bib-0017">17</a>, <a href="#hon70126-bib-0018" class="usa-link" aria-describedby="hon70126-bib-0018">18</a>, <a href="#hon70126-bib-0019" class="usa-link" aria-describedby="hon70126-bib-0019">19</a>]. The 2020 European LeukemiaNet recommendations state that discontinuation of TKIs may be considered in CML patients with durable DMR with the goal of achieving treatment‐free remission (TFR) [<a href="#hon70126-bib-0020" class="usa-link" aria-describedby="hon70126-bib-0020">20</a>]. However, there is a need to make both patients and clinicians more confident about TKI discontinuation, and this may be achieved by adopting a step‐by‐step approach in which patients are treated with a lower dose of a TKI during a DMR de‐escalation period before the TFR phase. A study investigating imatinib de‐escalation before TFR in patients with CML‐CP suggests that this stepwise approach is feasible [<a href="#hon70126-bib-0017" class="usa-link" aria-describedby="hon70126-bib-0017">17</a>]. Reduced‐dose TKI and TFR might also reduce the risk of cardiovascular events, which is higher with second‐ and third‐generation TKIs compared with imatinib [<a href="#hon70126-bib-0021" class="usa-link" aria-describedby="hon70126-bib-0021">21</a>].</p>
<p>Nilotinib is a second‐generation TKI that has been designed to be more selective against the <em>BCR::ABL1</em> tyrosine kinase than imatinib [<a href="#hon70126-bib-0022" class="usa-link" aria-describedby="hon70126-bib-0022">22</a>]. Although nilotinib is the first and only TKI approved for stopping therapy in patients with CML‐CP [<a href="#hon70126-bib-0023" class="usa-link" aria-describedby="hon70126-bib-0023">23</a>], nilotinib‐based TFR optimization strategy has not been formally studied.</p>
<p>Our phase II study (DANTE) aimed to assess the effect of reduced‐dose nilotinib (to half the standard dose) for 12 months in patients in TFR in patients with CML‐CP treated with first‐line nilotinib who reached a sustained DMR before entering the study. An interim analysis involving 40 patients with sustained DMR who entered the TFR phase showed that 67.5% of patients remained in major molecular response (MMR) or better 1 year after stopping nilotinib [<a href="#hon70126-bib-0024" class="usa-link" aria-describedby="hon70126-bib-0024">24</a>]. Here we present the final results from 90 patients who successfully completed nilotinib de‐escalation and ≥ 1 year of TFR.</p></section><section id="hon70126-sec-0020"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<section id="hon70126-sec-0030"><h3 class="pmc_sec_title">2.1. Study Design and Patients</h3>
<p>This prospective, single‐arm, phase II study (<a href="https://clinicaltrials.gov/ct2/show/NCT03874858" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03874858</a>) enrolled patients with CML‐CP at 27 centers in Italy. Key eligibility criteria included patients aged ≥ 18 years with a diagnosis of CML‐CP according to World Health Organization criteria treated with first‐line nilotinib 300 mg twice daily (bid) for ≥ 3 years who achieved sustained DMR for ≥ 1 year (Supporting Information <a href="#hon70126-sup-0001" class="usa-link">S1</a>: Table S1). Sustained DMR was defined as a molecular response ≥ 4.0 logs (MR<sup>4.0</sup>; i.e., <em>BCR::ABL1/ABL1</em> international scale [IS] ≤ 0.01%) in all of the last four <em>BCR::ABL1</em> real‐time quantitative reverse transcription polymerase chain reaction (qRT‐PCR) assessments with an interval between each assessment of 3–6 months. Inclusion criteria also included Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2. Key exclusion criteria included having a known atypical transcript, previous treatment resistance dose reductions/interruptions due to neutropenia or thrombocytopenia in the past 6 months, or impaired cardiac function (Supporting Information <a href="#hon70126-sup-0001" class="usa-link">S1</a>: Table S1).</p>
<p>The study consisted of four phases: screening (week −4 to week 0), nilotinib de‐escalation (week 0–48), TFR (week 48–144), and follow‐up (until week 144; Figure <a href="#hon70126-fig-0001" class="usa-link">1</a>). Ongoing treatment with nilotinib ≥ 400 mg/day was allowed at study entry. During nilotinib de‐escalation, patients were treated with nilotinib 300 mg once daily orally. At the end of the nilotinib de‐escalation phase, patients with sustained DMR entered the TFR phase and nilotinib was discontinued. Patients with a major molecular response (MMR; defined as <em>BCR::ABL1/ABL1</em> ≤ 0.1% IS) but without sustained DMR continued nilotinib 300 mg once daily. At any time, patients with loss of MMR returned to nilotinib 300 mg bid. During the TFR phase, <em>BCR::ABL1</em> levels were monitored monthly from week 52–96 and then every 3 months thereafter. During the follow‐up phase, patients who remained on a half‐dose of nilotinib after week 48 and patients with loss of MMR at any time during the study were monitored every 3 months until week 144.</p>
<figure class="fig xbox font-sm" id="hon70126-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907c/12333328/4356afbff70d/HON-43-e70126-g001.jpg" loading="lazy" id="jats-graphic-1" height="204" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/hon70126-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Study design. Bid, twice daily; CML‐CP, chronic myeloid leukemia in chronic phase; DMR, deep molecular response; IS, international scale; MMR, major molecular response; MR, molecular response; NIL, nilotinib; TFR, treatment‐free remission; qd, once daily.</p></figcaption></figure><p>The DANTE trial was designed, implemented, and reported in accordance with the International Council for Harmonization Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC and US Code of Federal Regulations Title 21), and with the ethical principles laid down in the Declaration of Helsinki. The protocol and proposed informed consent form were reviewed and approved by a properly constituted Independent Ethics Committee before the start of the study. Written informed consent was obtained from each patient.</p></section><section id="hon70126-sec-0040"><h3 class="pmc_sec_title">2.2. Outcomes</h3>
<p>The primary objective was to determine the percentage of patients in full TFR (FTFR) 96 weeks after the start of the de‐escalation phase. FTFR was defined as patients with MMR or better who remained in discontinuation during the TFR phase or were treated with half the standard dose of nilotinib. The study also explored whether suspending nilotinib or maintaining nilotinib at half the standard dose for those patients not eligible for TFR does not cause short‐ or long‐term harm. The transcription levels of <em>BCR::ABL1</em> were evaluated using standardized qRT‐PCR.</p>
<p>Secondary objectives included: the proportion of patients who remained in sustained DMR at the end of the de‐escalation phase (week 48); the proportion of patients who remained in DMR at the end of the de‐escalation phase (week 48) and at 96 weeks after the start of the de‐escalation phase; the proportion of patients with MMR or better at the end of the de‐escalation phase (week 48) and at 96 weeks after the start of the de‐escalation phase, regardless of whether they required reinitiation of treatment. Finally, safety was also investigated during the nilotinib de‐escalation phase, TFR phase, and reinitiation of treatment with nilotinib.</p>
<p>Adverse events (AEs) were assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Severe AEs were defined as CTCAE grade 3–4. Serious AEs were defined as those that were fatal or life‐threatening, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly, or required inpatient hospitalization. AEs of special interest (AESI) were defined as events (serious or non‐serious) that were of scientific and medical concern specific to the sponsor's product or program. These events were blood cholesterol increased, blood glucose increased, fluid retention, hepatic transaminase/bilirubin elevations, musculoskeletal pain, rash, and thrombocytopenia (Supporting Information <a href="#hon70126-sup-0001" class="usa-link">S1</a>: Table S2).</p></section><section id="hon70126-sec-0050"><h3 class="pmc_sec_title">2.3. Statistical Analysis</h3>
<p>Demonstration of successful FTFR of nilotinib was evaluated using the following hypotheses: H0: <em>p</em> ≤ 0.50, and H1: <em>p</em> &gt; 0.50, where <em>P</em> is the proportion of patients in successful FTFR 96 weeks after the start of the consolidation phase, computed as defined above. The null hypothesis was rejected, and successful FTFR was demonstrated if the lower limit of the 95% confidence interval (CI) was greater than 0.50. The study was designed with 80% power to test the null hypothesis that the rate of MMR or better at 96 weeks after the start of the study was <em>p</em> ≤ 0.50. The sample size was based on the one‐sided exact binomial test. If the true rate was <em>p</em> ≥ 0.65, a minimum of 93 patients would be required to test the null hypothesis H0: <em>p</em> ≤ 0.5, with a one‐sided alpha level of 2.5% and a power of 80%. Considering a dropout rate of 10% during the study, approximately 103 patients would have to be enrolled into the trial.</p>
<p>For patients with loss of MMR during TFR, the time to loss of MMR was computed in months as follows: date of <em>BCR::ABL1</em> qRT‐PCR assessments with loss of MMR minus baseline date of TFR (i.e. end date of previous period plus one day) plus one day. Patients without loss of MMR during TFR were censored at the end date of TFR or at the cut‐off date, whichever occurred first. The median time to event/censor and its corresponding two‐sided 95% CI was estimated using the Kaplan–Meier product‐limit method and presented as a Kaplan–Meier plot.</p>
<p>The primary efficacy analysis was performed on the full analysis set (FAS), defined as all patients who received at least one dose of study treatment. The safety set included all patients who received at least one dose of study treatment. Demographic and other baseline data are summarized descriptively for the FAS. Categorical data are presented as numerical frequencies and proportions of patients. For continuous data, mean, standard deviation, median, interquartile range (IQR), and range are presented.</p>
<p>Here, we report updated results collected until the cut‐off date of 8 February 2023, when all patients who entered the TFR phase had completed ≥ 1 year (48 weeks) of TFR, switched to full dose nilotinib, entered in follow‐up, or discontinued the study.</p></section></section><section id="hon70126-sec-0060"><h2 class="pmc_sec_title">3. Results</h2>
<section id="hon70126-sec-0070"><h3 class="pmc_sec_title">3.1. Patient Disposition</h3>
<p>Overall, 113 patients were screened and 107 entered the nilotinib de‐escalation phase and were included in the FAS (Figure <a href="#hon70126-fig-0002" class="usa-link">2</a>). Among these 107 patients, the median age was 52 years, 57% were male, and 104 (97.2%) had an ECOG PS score of 0 (Table <a href="#hon70126-tbl-0001" class="usa-link">1</a>). The nilotinib de‐escalation phase was completed by 98 patients (91.6%), while 9 patients (8.4%) discontinued permanently due to patient decision (<em>n</em> = 4), AEs (<em>n</em> = 3) or loss of MMR (<em>n</em> = 2). A total of 90 patients (84.1%) with sustained DMR at week 48 entered the TFR phase, while 8 patients (7.5%) maintained MMR but did not sustain DMR and entered the nilotinib half‐dose period (7 of these patients were in FTFR at 96 weeks).</p>
<figure class="fig xbox font-sm" id="hon70126-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907c/12333328/1d8f2db502b9/HON-43-e70126-g003.jpg" loading="lazy" id="jats-graphic-3" height="366" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/hon70126-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Patient disposition at data cut‐off (8 February 2023). AEs, adverse events; MMR, major molecular response; sDMR, sustained deep molecular response; TFR, treatment‐free remission.</p></figcaption></figure><section class="tw xbox font-sm" id="hon70126-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Baseline characteristics of patients entered in the nilotinib de‐escalation phase.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Total (<em>n</em> = 107)</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Age, years, median (range)</td>
<td align="center" valign="top" rowspan="1" colspan="1">52 (21–75)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Sex</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td>
<td align="center" valign="top" rowspan="1" colspan="1">61 (57.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td>
<td align="center" valign="top" rowspan="1" colspan="1">46 (43.0)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">ECOG PS</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Grade 0</td>
<td align="center" valign="top" rowspan="1" colspan="1">104 (97.2)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Grade 1</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (2.8)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Time from diagnosis to informed consent, years, median (range)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.5 (3–13)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Type of transcript at diagnosis</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">e13a2</td>
<td align="center" valign="top" rowspan="1" colspan="1">29 (27.1)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">e14a2</td>
<td align="center" valign="top" rowspan="1" colspan="1">53 (49.5)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Both/other</td>
<td align="center" valign="top" rowspan="1" colspan="1">9 (8.4)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
<td align="center" valign="top" rowspan="1" colspan="1">16 (15.0)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Sokal risk score at diagnosis</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Low (RR &lt; 0.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">46 (43.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Intermediate (RR 0.8–1.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">41 (38.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">High (RR &gt; 1.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">17 (15.9)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown/not evaluated</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (2.8)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Duration of last sustained MR<sup>4.5</sup> until screening, months, median (range)</td>
<td align="center" valign="top" rowspan="1" colspan="1">12.5 (0–94)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nilotinib exposure time before de‐escalation phase, years, median (range)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5.5 (3–13)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Last nilotinib dose before de‐escalation phase</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&lt; 300 mg bid</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (7.5)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">300 mg bid</td>
<td align="center" valign="top" rowspan="1" colspan="1">98 (91.6)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">None reported</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (0.9)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/hon70126-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="hon70126-note-0002"><p>
<em>Note:</em> Values are <em>n</em> (%) unless otherwise stated.</p></div>
<div class="fn" id="hon70126-note-0003"><p>Abbreviations: bid, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; MR, molecular response; RR, relative risk.</p></div>
</div></section></section><section id="hon70126-sec-0080"><h3 class="pmc_sec_title">3.2. Efficacy</h3>
<p>Of the 90 patients who entered the TFR phase, 64 (71.1%) remained in MMR or better after a median duration of 20.4 months (IQR 1.9–32.4). Of the remaining 26 patients (28.9%) who discontinued the TFR phase, 22 had a loss of MMR (which mostly occurred during the first 5 months), 3 did so by choice (patient decision), and 1 did so due to AEs. The median time‐to‐loss of MMR in the TFR phase was not reached (Figure <a href="#hon70126-fig-0003" class="usa-link">3</a>); in the TFR phase, the median time until loss of MMR was 3.6 months (IQR 2–19). At the 1‐year data cut‐off (8 February 2023), 71 patients (66.4%) were in FTFR at 96 weeks after the start of the nilotinib de‐escalation phase (the 64 patients who entered the TFR phase and remained in MMR or better plus the 7 patients who entered the nilotinib half‐dose period mentioned above); the 66.4% FTFR achieved the primary endpoint because the threshold of 50% was exceeded.</p>
<figure class="fig xbox font-sm" id="hon70126-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907c/12333328/1d5825928375/HON-43-e70126-g002.jpg" loading="lazy" id="jats-graphic-5" height="426" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/hon70126-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan–Meier plot of loss of major molecular response (MMR) in the treatment‐free remission phase. Circles represent censors. Patients at risk are those who had no censored observations and did not have loss of MMR at the considered timepoint.</p></figcaption></figure><p>Of the 24 patients who restarted nilotinib after MMR loss (2 patients from the de‐escalation phase and 22 from the TFR phase), 23 (95.8%) regained MMR after a median (IQR) of 11.0 (4.1–22.7) weeks and achieved MR<sup>4.0</sup> after a median (IQR) of 16.4 (4.7–40.1) weeks. The 24<sup>th</sup> patient did not achieve MMR or better. MR<sup>4.5</sup> was regained by 20 patients (83.3%) after a median of 25.8 weeks (IQR 8.1–67.7).</p>
<p>Fifty‐two of the 107 patients who entered the nilotinib de‐escalation phase (48.6%) remained in sustained DMR from the de‐escalation phase until week 96. No deaths or cases of disease progression were observed.</p></section><section id="hon70126-sec-0090"><h3 class="pmc_sec_title">3.3. Safety</h3>
<p>AEs of any grade that occurred at any time point during the study were observed in 81/107 patients (75.7%; Table <a href="#hon70126-tbl-0002" class="usa-link">2</a>). 20 patients (18.7%) had Grade 3 or 4 (severe) AEs, AEs, 6 (5.6%) had serious AEs, 46 (43.0%) had AESI, 27 (25.2%) had study drug‐related AEs, 12 (11.2%) had AEs leading to dose adjustment/temporary interruption, and 7 (6.5%) had AEs leading to permanent discontinuation of therapy.</p>
<section class="tw xbox font-sm" id="hon70126-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>Summary of patients with adverse events.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Safety set (<em>n</em> = 107)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">De‐escalation (<em>n</em> = 107)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">TFR<a href="#hon70126-note-0005" class="usa-link">
<sup>a</sup>
</a> (<em>n</em> = 90)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Half‐dose follow‐up (<em>n</em> = 8)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Full‐dose follow‐up (<em>n</em> = 24)</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">AEs</td>
<td align="center" valign="top" rowspan="1" colspan="1">81 (75.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">44 (41.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">64 (71.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 (75.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">17 (70.8)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Grade 3 or 4 (severe) AEs</td>
<td align="center" valign="top" rowspan="1" colspan="1">20 (18.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (9.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 (13.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (25.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (8.3)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Serious AEs</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 (5.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (4.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (1.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">AESI</td>
<td align="center" valign="top" rowspan="1" colspan="1">46 (43.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">18 (16.8)</td>
<td align="center" valign="top" rowspan="1" colspan="1">40 (44.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (25.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">9 (37.5)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Drug‐related AEs</td>
<td align="center" valign="top" rowspan="1" colspan="1">27 (25.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">16 (15.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">17 (18.9)<a href="#hon70126-note-0006" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (37.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 (25.0)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">AEs leading to treatment dosage adjustment/temporary interruption</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 (11.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">7 (6.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (1.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (12.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (20.8)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">AEs leading to permanent discontinuation of the study therapy</td>
<td align="center" valign="top" rowspan="1" colspan="1">7 (6.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (3.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (1.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (12.5)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (8.3)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fatal AEs</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/hon70126-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="hon70126-note-0004"><p>
<em>Note:</em> Values are <em>n</em> (%). Only AEs that started or worsened after the start of the de‐escalation phase (i.e. first nilotinib dose 300 mg qd) were considered. Severity of AEs was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</p></div>
<div class="fn" id="hon70126-note-0007"><p>Abbreviations: AEs, adverse events; AESI, adverse events of special interest; TKI, tyrosine kinase inhibitor; TRF, treatment‐free remission; qd, once daily.</p></div>
<div class="fn" id="hon70126-note-0005">
<sup>
<sup>a</sup>
</sup><p class="display-inline">Includes patients who restarted treatment after TFR failure.</p>
</div>
<div class="fn" id="hon70126-note-0006">
<sup>
<sup>b</sup>
</sup><p class="display-inline">8 patients had musculoskeletal and connective tissue disorders related to TKI withdrawal syndrome.</p>
</div>
</div></section><p>During the nilotinib de‐escalation phase, AEs of any grade were observed in 44 of 107 patients (41.1%; Table <a href="#hon70126-tbl-0002" class="usa-link">2</a>). The most common AEs by system organ class during de‐escalation were autoimmune musculoskeletal and connective tissue disorders (12.2%). 10 patients (9.4%) had severe AEs, and 5 patients (4.7%) had serious AEs (unstable angina, myocardial ischemia, COVID‐19 pneumonia, skin ulcer, acetabulum fracture, femur fracture and separation of the pubic symphysis [some patients had more than one event]). Two serious AEs (grade 3 myocardial ischemia and grade 4 unstable angina) were considered related to nilotinib treatment; both events were resolved with no intervention and permanent nilotinib discontinuation, respectively. Eighteen patients (16.8%) had AESI, 16 (15.0%) had study drug‐related AEs, 7 (6.5%) had AEs leading to dose adjustment/temporary interruption, and four (3.7%) had AEs leading to permanent discontinuation of therapy.</p>
<p>During the TFR phase, AEs of any grade were reported in 64 of 90 patients (71.1%; Table <a href="#hon70126-tbl-0002" class="usa-link">2</a>). The most common AEs of any grade by system organ class were musculoskeletal and connective tissue disorders (38.9%; Table <a href="#hon70126-tbl-0003" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="hon70126-tbl-0003"><h4 class="obj_head">TABLE 3.</h4>
<div class="caption p"><p>Most common adverse events occurring in &gt; 5% of patients at treatment‐free remission by system organ class.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom">
<tr>
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th style="border-bottom:solid 1px #000000" colspan="5" align="center" valign="bottom" rowspan="1">Total (<em>n</em> = 90)</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Overall</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Grade 1</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Grade 2</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Grade 3</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Grade 4</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total AEs</td>
<td align="center" valign="top" rowspan="1" colspan="1">64 (71.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">56 (62.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">30 (33.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 (13.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Musculoskeletal and connective tissue disorders</td>
<td align="center" valign="top" rowspan="1" colspan="1">35 (38.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">28 (31.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (16.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (1.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Arthralgia</td>
<td align="center" valign="top" rowspan="1" colspan="1">14 (15.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 (13.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (4.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (1.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Myalgia</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 (13.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (11.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (4.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Laboratory investigations</td>
<td align="center" valign="top" rowspan="1" colspan="1">20 (22.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (16.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (5.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (8.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lipase increased</td>
<td align="center" valign="top" rowspan="1" colspan="1">9 (10.0)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (3.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 (6.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Amylase increased</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 (6.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (4.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Infections and infestations</td>
<td align="center" valign="top" rowspan="1" colspan="1">19 (21.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (16.7)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (5.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">COVID‐19</td>
<td align="center" valign="top" rowspan="1" colspan="1">13 (14.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">11 (12.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Metabolism and nutrition disorders</td>
<td align="center" valign="top" rowspan="1" colspan="1">13 (14.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">12 (13.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (4.4)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nervous system disorders</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (11.1)</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 (8.9)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (3.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Headache</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (5.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (5.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Cardiac disorders</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (5.6)</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (3.3)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (2.2)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/hon70126-tbl-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="hon70126-note-0008"><p>
<em>Note:</em> Values are <em>n</em> (%).</p></div>
<div class="fn" id="hon70126-note-0009"><p>Abbreviation: AEs, adverse events.</p></div>
</div></section><p>Twelve patients (13.3%) had severe AEs, and one patient (1.1%) had a serious AE (pneumonia). Forty patients (44.4%) had AESI, the most common of which were musculoskeletal pain (31.1%), blood cholesterol increase (6.7%) and high blood glucose levels (5.6%). During the half‐dose follow‐up, 6 patients (75%) had AEs, but only three of these experienced a study drug‐related AE (Table <a href="#hon70126-tbl-0002" class="usa-link">2</a>). During the full‐dose follow‐up phase, AEs were observed in 17 patients (70.8%; Table <a href="#hon70126-tbl-0002" class="usa-link">2</a>), none of which were serious; 6 patients (25%) experienced a study drug‐related AE.</p></section></section><section id="hon70126-sec-0100"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>The 96‐week results of the DANTE study demonstrate that de‐escalation of nilotinib can be a successful dose‐optimization strategy for patients with CML‐CP and sustained DMR. Two‐thirds of patients were in FTFR at 96 weeks after the start of the nilotinib de‐escalation phase, meeting the primary endpoint of the study. Furthermore, 71% of patients remained in MMR or better after a median treatment duration of 20 months, and loss of MMR during de‐escalation occurred in only 2 of 107 patients who entered the nilotinib de‐escalation phase. Nilotinib de‐escalation also appeared to be safe, with serious AEs occurring in five patients during the de‐escalation phase and in only one patient during the TFR phase.</p>
<p>The majority of previous TFR studies in patients with CML discontinued TKI treatment abruptly [<a href="#hon70126-bib-0013" class="usa-link" aria-describedby="hon70126-bib-0013">13</a>, <a href="#hon70126-bib-0016" class="usa-link" aria-describedby="hon70126-bib-0016">16</a>, <a href="#hon70126-bib-0025" class="usa-link" aria-describedby="hon70126-bib-0025">25</a>], whereas nilotinib treatment was de‐escalated in our study. In these previous studies, relapse‐free survival rates were 38.0%–51.6% at 11–60 months after discontinuation [<a href="#hon70126-bib-0013" class="usa-link" aria-describedby="hon70126-bib-0013">13</a>, <a href="#hon70126-bib-0016" class="usa-link" aria-describedby="hon70126-bib-0016">16</a>, <a href="#hon70126-bib-0025" class="usa-link" aria-describedby="hon70126-bib-0025">25</a>]. In comparison, 71.1% of patients in our study who entered TFR remained in ≥ MMR after a median duration of 20.4 months. The Stop Imatinib trial (STIM1) was the first to demonstrate the potential for patients who achieve DMR to remain in remission after stopping TKI therapy [<a href="#hon70126-bib-0013" class="usa-link" aria-describedby="hon70126-bib-0013">13</a>]. In that trial, stopping criteria were imatinib treatment for ≥ 2 years and undetectable minimal residual disease for ≥ 2 years. In the European Stop Kinase Inhibitor (EURO‐SKI) trial, patients received imatinib, nilotinib or dasatinib [<a href="#hon70126-bib-0025" class="usa-link" aria-describedby="hon70126-bib-0025">25</a>, <a href="#hon70126-bib-0026" class="usa-link" aria-describedby="hon70126-bib-0026">26</a>]. The duration of TKI treatment before enrollment in EURO‐SKI was required to be ≥ 3 years and no PCR results &gt; 0.01% (corresponding to MR<sup>4.0</sup>) in the last year before TKI discontinuation was allowed. Finally, the ENESTfreedom trial enrolled patients with MR<sup>4.5</sup> and ≥ 2 years of front‐line nilotinib therapy [<a href="#hon70126-bib-0016" class="usa-link" aria-describedby="hon70126-bib-0016">16</a>]. Patients with sustained DMR during the full‐dose 1‐year consolidation phase were eligible to stop treatment and enter the TFR phase.</p>
<p>Despite these previous study data supporting TKI discontinuation in patients with CML‐CP, both patients and clinicians appear to have concerns about attempting TFR [<a href="#hon70126-bib-0027" class="usa-link" aria-describedby="hon70126-bib-0027">27</a>, <a href="#hon70126-bib-0028" class="usa-link" aria-describedby="hon70126-bib-0028">28</a>]. Sharf and colleagues reported that 56%–59% of patients experienced fear, anxiety or depression during TFR or when they reinitiated TKI therapy [<a href="#hon70126-bib-0029" class="usa-link" aria-describedby="hon70126-bib-0029">29</a>]. Therefore, de‐escalation of nilotinib therapy may present a more feasible and reassuring option for these patients.</p>
<p>The findings of our study are consistent with those of the De‐Escalation and Stopping Treatment with Imatinib, Nilotinib or Dasatinib (DESTINY) study, where treatment was de‐escalated to half the standard dose for 12 months, then stopped for a further 24 months [<a href="#hon70126-bib-0017" class="usa-link" aria-describedby="hon70126-bib-0017">17</a>]. In the final analysis of DESTINY, recurrence‐free survival at 36 months was 72% in MR<sup>4.0</sup> patients and 36% in MMR patients [<a href="#hon70126-bib-0017" class="usa-link" aria-describedby="hon70126-bib-0017">17</a>].</p>
<p>Data from three real‐world studies also report de‐escalation of TKI therapy in patients with CML‐CP [<a href="#hon70126-bib-0030" class="usa-link" aria-describedby="hon70126-bib-0030">30</a>, <a href="#hon70126-bib-0031" class="usa-link" aria-describedby="hon70126-bib-0031">31</a>, <a href="#hon70126-bib-0032" class="usa-link" aria-describedby="hon70126-bib-0032">32</a>]. In a retrospective analysis of 77 patients who discontinued TKIs, 26 were managed with a low‐dose TKI before stopping treatment [<a href="#hon70126-bib-0030" class="usa-link" aria-describedby="hon70126-bib-0030">30</a>]. After a median follow‐up of 61.5 months, the 60‐month TFR rate was 58.8%. In a real‐world study of 52 patients on low‐dose ponatinib, one of 15 patients who obtained DMR also achieved TFR [<a href="#hon70126-bib-0031" class="usa-link" aria-describedby="hon70126-bib-0031">31</a>]. In another real‐world study of 248 patients who discontinued low‐dose TKI treatment, 172 patients (69.4%) were still in TFR after a median follow‐up of 24.9 months [<a href="#hon70126-bib-0032" class="usa-link" aria-describedby="hon70126-bib-0032">32</a>].</p>
<p>Recent studies have shown that a significant proportion of patients can achieve a DMR with TKIs, and that treatment discontinuation can be successfully achieved in approximately 50% of these patients. However, the remaining 50% require the reintroduction of TKI therapy. Although around 90%–95% of patients who experience molecular recurrence regain their initial molecular level after restarting TKI therapy, success rates of a second attempt at TFR tend to be lower than those of the first, with reports of 35% at 12 months [<a href="#hon70126-bib-0033" class="usa-link" aria-describedby="hon70126-bib-0033">33</a>], 44.3%, 38.5%, and 33.2% at 24, 36, and 48 months, respectively [<a href="#hon70126-bib-0034" class="usa-link" aria-describedby="hon70126-bib-0034">34</a>], and 21.5% at 6 months [<a href="#hon70126-bib-0035" class="usa-link" aria-describedby="hon70126-bib-0035">35</a>].</p>
<p>The DANTE trial consists of two stages, a Treatment‐Free Remission 1 (TFR1) stage, reported here, and a Treatment‐Free Remission 2 (TFR2) stage. The purpose of the TFR2 stage is to evaluate whether the use of asciminib in combination with full‐dose nilotinib after failure of a first attempt at TFR can lead to higher and more durable TFR rates after a second attempt at TKI discontinuation than those reported in other studies. Asciminib is a first‐in‐class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, with demonstrated clinical efficacy in patients who have received more than two TKIs [<a href="#hon70126-bib-0036" class="usa-link" aria-describedby="hon70126-bib-0036">36</a>]. The TFR2 stage will enroll two cohorts of patients: an internal cohort comprising patients who failed a first attempt at TFR during the TFR1 stage of the present study, and an external cohort of patients who failed their first attempt following discontinuation of nilotinib outside of this study. The study is ongoing, and the results of TFR2 are eagerly anticipated.</p>
<p>Nilotinib de‐escalation was well tolerated in our study. The most common AEs by system organ class during the de‐escalation and TFR phase were autoimmune musculoskeletal and connective tissue disorders (12.2% and 38.9%, respectively). During the TFR phase, autoimmune musculoskeletal and connective tissue disorders were grade 1–2 in all but one patient, who had grade 3 arthralgia, which was managed with corticosteroid treatment. This safety profile is also consistent with that reported in DESTINY, in which 39.7% of patients reported musculoskeletal symptoms during the first 12 months of stopping therapy [<a href="#hon70126-bib-0017" class="usa-link" aria-describedby="hon70126-bib-0017">17</a>]. Musculoskeletal and/or joint pain occurring after TKI discontinuation, known as TKI withdrawal syndrome, is thought to be an off‐target effect of TKIs [<a href="#hon70126-bib-0020" class="usa-link" aria-describedby="hon70126-bib-0020">20</a>]. In most patients, such symptoms are mild and self‐limiting; however, some patients may require treatment with acetaminophen (paracetamol), nonsteroidal anti‐inflammatory drugs, or oral corticosteroids. Progressive de‐escalation of the TKI dose, rather than abruptly interrupting therapy, may be useful for avoiding withdrawal syndrome symptoms without jeopardizing the possibility of maintaining a good response and achieving TFR [<a href="#hon70126-bib-0032" class="usa-link" aria-describedby="hon70126-bib-0032">32</a>]. Potential benefits of a longer treatment period with a reduced dosage, such as leukemic stem cell exhaustion and reduced AEs, could further support this strategy [<a href="#hon70126-bib-0017" class="usa-link" aria-describedby="hon70126-bib-0017">17</a>].</p>
<p>The main limitations of our study are the small sample size and the lack of a comparator group.</p></section><section id="hon70126-sec-0110"><h2 class="pmc_sec_title">5. Conclusions</h2>
<p>The phase II DANTE study is the first to prospectively investigate the use of TKI dose de‐escalation before stopping treatment. The final results showed that two‐thirds of patients who entered the de‐escalation phase achieved FTFR at 96 weeks after the start of the de‐escalation period, with 71% of patients remaining disease‐free at 1 year. These findings suggest that de‐escalation of nilotinib before attempting TFR in CML‐CP patients with sustained DMR can be a successful dose‐optimization strategy. Based on the results of this trial and previous real‐world evidence, this treatment optimization strategy may be applied safely in clinical practice.</p></section><section id="hon70126-sec-0120"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>A.I., M.B., F.S., G.S., G.R. are members of the DANTE protocol steering committee, enrolled patients, contributed to the preparation of the manuscript and study design, and read and approved drafts and the final manuscript. E.A., F.P., I.A., P.S., M.C., S.G., B.S., M.M., S.S., I.C., enrolled patients, read and approved drafts and final manuscript. D.V., A.P.N., A.M., P.C. as employees of Novartis Farma Italy designed and conducted the study, as well as collected, analyzed, and interpreted the data, contributed to the preparation of the manuscript, and read and approved drafts and the final manuscript.</p></section><section id="hon70126-sec-0140"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>During the last 2 years, A.I. received honoraria for lectures from Incyte, Novartis, Bristol Myers Squibb, GSK, Pfizer and AOP Health, and for advisory boards from Incyte, Novartis, Bristol Myers Squibb and AOP Health. M.B. has received honoraria from Novartis, Incyte, Bristol Myers Squibb, GSK, Pfizer and AOP, and advisory board honoraria from Novartis, Incyte, Bristol Myers Squibb, AOP and GSK. F.S. has received honoraria from Incyte, Novartis and Pfizer. E.A. has participated in consultancies and/or advisory boards with Ascentage, Bristol Myers Squibb, Incyte, Pfizer and Takeda. F.P. received honoraria during the last 2 years for lectures from Incyte, Novartis, Bristol Myers Squibb, and for advisory boards from Incyte, Novartis. PS received honoraria from Novartis, Abbvie, J and J and Beigene. M.C. has received honoraria from Novartis, Incyte, Amgen, Otsuka, Astellas, Servier, Italfarmaco, Abbvie, Janssen and Jazz. S.G. received honoraria from Novartis, Incyte, Abbvie, Janssen, Pfizer, Astra Zeneca, Beigene, Lilly, Roche, and Jazz. B.S. received honoraria from Novartis, Incyte, Amgen, Sanofi, Pfizer. IC received honoraria from Novartis, Incyte, Bristol Myers Squibb, Pfizer. G.S. is on a speakers' bureau for Novartis. D.V., A.P.N., A.M. and P.C. are employees of Novartis. G.R. has received honoraria from Novartis, Incyte, Bristol Myers Squibb, Pfizer, Angelini and Sun Pharma. I.A., M.M., and S.S. have no competing financial interests.</p></section><section id="hon70126-sec-0170"><h2 class="pmc_sec_title">Peer Review</h2>
<p>The peer review history for this article is available at <a href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70126</a>.</p></section><section id="sec15"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="hon70126-sup-0001"><div class="caption p"><p>
Supporting Information S1
</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12333328/bin/HON-43-e70126-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70126-s001.pdf</a><sup> (152.3KB, pdf) </sup>
</div></div></section></section><section id="hon70126-sec-0130" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>We would like to thank the patients enrolled in this study and their families, as well as all the participating investigators and their site teams. We would like to thank Carmen Innes, BSc, of Springer Healthcare, who wrote the outline and subsequent drafts of this manuscript, and Ray Hill, independent medical writer, who provided journal styling before submission. This medical writing assistance was funded by Novartis. We would also like to thank Vincenza Vinaccia, MPM, of Novartis Farma SpA, for support and assistance in the review process and Michela Magnoli, OPIS s.r.l., for the statistical analysis. The DANTE study, manuscript development, and the open‐access publishing fee were funded by Novartis Farma SpA Italy. Open access funding provided by BIBLIOSAN.</p></section><section id="notes1"><p>


Iurlo, Alessandra
, Breccia Massimo, Stagno Fabio, et al. 2025. “Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study.”
Hematological Oncology: e70126. 10.1002/hon.70126.
</p>
<section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="hon70126-note-0001"><p>
<strong>Funding:</strong> The DANTE study, manuscript development, the open‐access publishing fee, and medical writing assistance were funded by Novartis Farma SpA Italy.</p></div></div></section></section><section id="hon70126-sec-0160"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>Deidentified data that support the findings of this study can be made available on request to the corresponding author, Alessandra Iurlo (<span>alessandra.iurlo@policlinico.mi.it</span>).</p></section><section id="hon70126-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="hon70126-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="hon70126-bib-0001">
<span class="label">1.</span><cite>
Soverini S., de Benedittis C., Mancini M., and Martinelli G., “Mutations in the BCR‐ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia,” supplement, Clinical Lymphoma, Myeloma and Leukemia
15, no. Suppl (2015): S120–S128, 10.1016/j.clml.2015.02.035.</cite> [<a href="https://doi.org/10.1016/j.clml.2015.02.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26297264/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Lymphoma,%20Myeloma%20and%20Leukemia&amp;title=Mutations%20in%20the%20BCR%E2%80%90ABL1%20Kinase%20Domain%20and%20Elsewhere%20in%20Chronic%20Myeloid%20Leukemia&amp;author=S.%20Soverini&amp;author=C.%20de%20Benedittis&amp;author=M.%20Mancini&amp;author=G.%20Martinelli&amp;volume=15&amp;issue=Suppl&amp;publication_year=2015&amp;pages=S120-S128&amp;pmid=26297264&amp;doi=10.1016/j.clml.2015.02.035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0002">
<span class="label">2.</span><cite>
Osman A. E. G. and Deininger M. W., “Chronic Myeloid Leukemia: Modern Therapies, Current Challenges and Future Directions,” Blood Reviews
49 (2021): 100825, 10.1016/j.blre.2021.100825.
</cite> [<a href="https://doi.org/10.1016/j.blre.2021.100825" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8563059/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33773846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Reviews&amp;title=Chronic%20Myeloid%20Leukemia:%20Modern%20Therapies,%20Current%20Challenges%20and%20Future%20Directions&amp;author=A.%20E.%20G.%20Osman&amp;author=M.%20W.%20Deininger&amp;volume=49&amp;publication_year=2021&amp;pages=100825&amp;pmid=33773846&amp;doi=10.1016/j.blre.2021.100825&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0003">
<span class="label">3.</span><cite>
Eden R. E. and Coviello J. M., “Chronic Myelogenous Leukemia,” in Statpearls. Treasure Island FL (StatPearls Publishing LLC., 2024).</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/30285354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Statpearls.%20Treasure%20Island%20FL&amp;author=R.%20E.%20Eden&amp;author=J.%20M.%20Coviello&amp;publication_year=2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0004">
<span class="label">4.</span><cite>
Höglund M., Sandin F., and Simonsson B., “Epidemiology of Chronic Myeloid Leukaemia: An Update,” supplement, Annals of Hematology
94, no. S2 (2015): S241–S247, 10.1007/s00277-015-2314-2.
</cite> [<a href="https://doi.org/10.1007/s00277-015-2314-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25814090/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Hematology&amp;title=Epidemiology%20of%20Chronic%20Myeloid%20Leukaemia:%20An%20Update&amp;author=M.%20H%C3%B6glund&amp;author=F.%20Sandin&amp;author=B.%20Simonsson&amp;volume=94&amp;issue=S2&amp;publication_year=2015&amp;pages=S241-S247&amp;pmid=25814090&amp;doi=10.1007/s00277-015-2314-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0005">
<span class="label">5.</span><cite>
Senapati J., Sasaki K., Issa G. C., et al., “Management of Chronic Myeloid Leukemia in 2023 ‐ Common Ground and Common Sense,” Blood Cancer Journal
13, no. 1 (2023): 58, 10.1038/s41408-023-00823-9.
</cite> [<a href="https://doi.org/10.1038/s41408-023-00823-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10123066/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37088793/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20Journal&amp;title=Management%20of%20Chronic%20Myeloid%20Leukemia%20in%202023%20%E2%80%90%20Common%20Ground%20and%20Common%20Sense&amp;author=J.%20Senapati&amp;author=K.%20Sasaki&amp;author=G.%20C.%20Issa&amp;volume=13&amp;issue=1&amp;publication_year=2023&amp;pages=58&amp;pmid=37088793&amp;doi=10.1038/s41408-023-00823-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0006">
<span class="label">6.</span><cite>
Bower H., Björkholm M., Dickman P. W., Höglund M., Lambert P. C., and Andersson T. M., “Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population,” Journal of Clinical Oncology
34, no. 24 (2016): 2851–2857, 10.1200/JCO.2015.66.2866.
</cite> [<a href="https://doi.org/10.1200/JCO.2015.66.2866" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27325849/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Life%20Expectancy%20of%20Patients%20With%20Chronic%20Myeloid%20Leukemia%20Approaches%20the%20Life%20Expectancy%20of%20the%20General%20Population&amp;author=H.%20Bower&amp;author=M.%20Bj%C3%B6rkholm&amp;author=P.%20W.%20Dickman&amp;author=M.%20H%C3%B6glund&amp;author=P.%20C.%20Lambert&amp;volume=34&amp;issue=24&amp;publication_year=2016&amp;pages=2851-2857&amp;pmid=27325849&amp;doi=10.1200/JCO.2015.66.2866&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0007">
<span class="label">7.</span><cite>
Dusetzina S. B., Winn A. N., Abel G. A., Huskamp H. A., and Keating N. L., “Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia,” Journal of Clinical Oncology
32, no. 4 (2014): 306–311, 10.1200/jco.2013.52.9123.
</cite> [<a href="https://doi.org/10.1200/jco.2013.52.9123" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24366936/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Cost%20Sharing%20and%20Adherence%20to%20Tyrosine%20Kinase%20Inhibitors%20for%20Patients%20With%20Chronic%20Myeloid%20Leukemia&amp;author=S.%20B.%20Dusetzina&amp;author=A.%20N.%20Winn&amp;author=G.%20A.%20Abel&amp;author=H.%20A.%20Huskamp&amp;author=N.%20L.%20Keating&amp;volume=32&amp;issue=4&amp;publication_year=2014&amp;pages=306-311&amp;pmid=24366936&amp;doi=10.1200/jco.2013.52.9123&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0008">
<span class="label">8.</span><cite>
Efficace F. and Cannella L., “The Value of Quality of Life Assessment in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors,” Hematology‐American Society of Hematology Education Program
2016, no. 1 (2016): 170–179, 10.1182/asheducation-2016.1.170.
</cite> [<a href="https://doi.org/10.1182/asheducation-2016.1.170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6142524/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27913477/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematology%E2%80%90American%20Society%20of%20Hematology%20Education%20Program&amp;title=The%20Value%20of%20Quality%20of%20Life%20Assessment%20in%20Chronic%20Myeloid%20Leukemia%20Patients%20Receiving%20Tyrosine%20Kinase%20Inhibitors&amp;author=F.%20Efficace&amp;author=L.%20Cannella&amp;volume=2016&amp;issue=1&amp;publication_year=2016&amp;pages=170-179&amp;pmid=27913477&amp;doi=10.1182/asheducation-2016.1.170&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0009">
<span class="label">9.</span><cite>
Thanarajasingam G., Minasian L. M., Baron F., et al., “Beyond Maximum Grade: Modernising the Assessment and Reporting of Adverse Events in Haematological Malignancies,” Lancet Haematology
5, no. 11 (2018): e563–e598, 10.1016/s2352-3026(18)30051-6.
</cite> [<a href="https://doi.org/10.1016/s2352-3026(18)30051-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6261436/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29907552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematology&amp;title=Beyond%20Maximum%20Grade:%20Modernising%20the%20Assessment%20and%20Reporting%20of%20Adverse%20Events%20in%20Haematological%20Malignancies&amp;author=G.%20Thanarajasingam&amp;author=L.%20M.%20Minasian&amp;author=F.%20Baron&amp;volume=5&amp;issue=11&amp;publication_year=2018&amp;pages=e563-e598&amp;pmid=29907552&amp;doi=10.1016/s2352-3026(18)30051-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0010">
<span class="label">10.</span><cite>
Cattaneo D., Bucelli C., Bellani V., Mora B., and Iurlo A., “Treatment‐Free Remission as a New Goal in the Management of Chronic Myeloid Leukemia: Clinical and Biological Aspects,” Hematological Oncology
42, no. 5 (2024): e3309, 10.1002/hon.3309.
</cite> [<a href="https://doi.org/10.1002/hon.3309" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39275966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematological%20Oncology&amp;title=Treatment%E2%80%90Free%20Remission%20as%20a%20New%20Goal%20in%20the%20Management%20of%20Chronic%20Myeloid%20Leukemia:%20Clinical%20and%20Biological%20Aspects&amp;author=D.%20Cattaneo&amp;author=C.%20Bucelli&amp;author=V.%20Bellani&amp;author=B.%20Mora&amp;author=A.%20Iurlo&amp;volume=42&amp;issue=5&amp;publication_year=2024&amp;pages=e3309&amp;pmid=39275966&amp;doi=10.1002/hon.3309&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0011">
<span class="label">11.</span><cite>
Chen Y., Zou J., Cheng F., and Li W., “Treatment‐Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells,” Frontiers Oncology
11 (2021): 769730, 10.3389/fonc.2021.769730.</cite> [<a href="https://doi.org/10.3389/fonc.2021.769730" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8581243/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34778088/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20Oncology&amp;title=Treatment%E2%80%90Free%20Remission%20in%20Chronic%20Myeloid%20Leukemia%20and%20New%20Approaches%20by%20Targeting%20Leukemia%20Stem%20Cells&amp;author=Y.%20Chen&amp;author=J.%20Zou&amp;author=F.%20Cheng&amp;author=W.%20Li&amp;volume=11&amp;publication_year=2021&amp;pages=769730&amp;pmid=34778088&amp;doi=10.3389/fonc.2021.769730&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0012">
<span class="label">12.</span><cite>
Abruzzese E., Aureli S., Bondanini F., et al., “Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer,” Journal of Clinical Medicine
11, no. 7 (2022): 1801, 10.3390/jcm11071801.
</cite> [<a href="https://doi.org/10.3390/jcm11071801" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8999799/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35407407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Medicine&amp;title=Chronic%20Myeloid%20Leukemia%20and%20Pregnancy:%20When%20Dreams%20Meet%20Reality.%20State%20of%20the%20Art,%20Management%20and%20Outcome%20of%2041%20Cases,%20Nilotinib%20Placental%20Transfer&amp;author=E.%20Abruzzese&amp;author=S.%20Aureli&amp;author=F.%20Bondanini&amp;volume=11&amp;issue=7&amp;publication_year=2022&amp;pages=1801&amp;pmid=35407407&amp;doi=10.3390/jcm11071801&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0013">
<span class="label">13.</span><cite>
Etienne G., Guilhot J., Rea D., et al., “Long‐Term Follow‐Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia,” Journal of Clinical Oncology
35, no. 3 (2017): 298–305, 10.1200/jco.2016.68.2914.
</cite> [<a href="https://doi.org/10.1200/jco.2016.68.2914" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28095277/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Long%E2%80%90Term%20Follow%E2%80%90Up%20of%20the%20French%20Stop%20Imatinib%20(STIM1)%20Study%20in%20Patients%20With%20Chronic%20Myeloid%20Leukemia&amp;author=G.%20Etienne&amp;author=J.%20Guilhot&amp;author=D.%20Rea&amp;volume=35&amp;issue=3&amp;publication_year=2017&amp;pages=298-305&amp;pmid=28095277&amp;doi=10.1200/jco.2016.68.2914&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0014">
<span class="label">14.</span><cite>
Rea D., Nicolini F. E., Tulliez M., et al., “Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia: Interim Analysis of the STOP 2G‐TKI Study,” Blood
129, no. 7 (2017): 846–854, 10.1182/blood-2016-09-742205.
</cite> [<a href="https://doi.org/10.1182/blood-2016-09-742205" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27932374/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Discontinuation%20of%20Dasatinib%20or%20Nilotinib%20in%20Chronic%20Myeloid%20Leukemia:%20Interim%20Analysis%20of%20the%20STOP%202G%E2%80%90TKI%20Study&amp;author=D.%20Rea&amp;author=F.%20E.%20Nicolini&amp;author=M.%20Tulliez&amp;volume=129&amp;issue=7&amp;publication_year=2017&amp;pages=846-854&amp;pmid=27932374&amp;doi=10.1182/blood-2016-09-742205&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0015">
<span class="label">15.</span><cite>
Rousselot P., Charbonnier A., Cony‐Makhoul P., et al., “Loss of Major Molecular Response as a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic‐phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease,” Journal of Clinical Oncology
32, no. 5 (2014): 424–430, 10.1200/jco.2012.48.5797.
</cite> [<a href="https://doi.org/10.1200/jco.2012.48.5797" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24323036/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Loss%20of%20Major%20Molecular%20Response%20as%20a%20Trigger%20for%20Restarting%20Tyrosine%20Kinase%20Inhibitor%20Therapy%20in%20Patients%20With%20Chronic%E2%80%90phase%20Chronic%20Myelogenous%20Leukemia%20Who%20Have%20Stopped%20Imatinib%20After%20Durable%20Undetectable%20Disease&amp;author=P.%20Rousselot&amp;author=A.%20Charbonnier&amp;author=P.%20Cony%E2%80%90Makhoul&amp;volume=32&amp;issue=5&amp;publication_year=2014&amp;pages=424-430&amp;pmid=24323036&amp;doi=10.1200/jco.2012.48.5797&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0016">
<span class="label">16.</span><cite>
Hochhaus A., Masszi T., Giles F. J., et al., “Treatment‐Free Remission Following Frontline Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From the Enestfreedom Study,” Leukemia
31, no. 7 (2017): 1525–1531, 10.1038/leu.2017.63.
</cite> [<a href="https://doi.org/10.1038/leu.2017.63" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5508077/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28218239/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Treatment%E2%80%90Free%20Remission%20Following%20Frontline%20Nilotinib%20in%20Patients%20With%20Chronic%20Myeloid%20Leukemia%20in%20Chronic%20Phase:%20Results%20From%20the%20Enestfreedom%20Study&amp;author=A.%20Hochhaus&amp;author=T.%20Masszi&amp;author=F.%20J.%20Giles&amp;volume=31&amp;issue=7&amp;publication_year=2017&amp;pages=1525-1531&amp;pmid=28218239&amp;doi=10.1038/leu.2017.63&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0017">
<span class="label">17.</span><cite>
Clark R. E., Polydoros F., Apperley J. F., et al., “De‐escalation of Tyrosine Kinase Inhibitor Therapy Before Complete Treatment Discontinuation in Patients With Chronic Myeloid Leukaemia (DESTINY): A Non‐Randomised, Phase 2 Trial,” Lancet Haematology
6, no. 7 (2019): e375–e383, 10.1016/s2352-3026(19)30094-8.
</cite> [<a href="https://doi.org/10.1016/s2352-3026(19)30094-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31201085/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematology&amp;title=De%E2%80%90escalation%20of%20Tyrosine%20Kinase%20Inhibitor%20Therapy%20Before%20Complete%20Treatment%20Discontinuation%20in%20Patients%20With%20Chronic%20Myeloid%20Leukaemia%20(DESTINY):%20A%20Non%E2%80%90Randomised,%20Phase%202%20Trial&amp;author=R.%20E.%20Clark&amp;author=F.%20Polydoros&amp;author=J.%20F.%20Apperley&amp;volume=6&amp;issue=7&amp;publication_year=2019&amp;pages=e375-e383&amp;pmid=31201085&amp;doi=10.1016/s2352-3026(19)30094-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0018">
<span class="label">18.</span><cite>
Campiotti L., Suter M. B., Guasti L., et al., “Imatinib Discontinuation in Chronic Myeloid Leukaemia Patients With Undetectable BCR‐ABL Transcript Level: A Systematic Review and a Meta‐Analysis,” European Journal of Cancer
77 (2017): 48–56, 10.1016/j.ejca.2017.02.028.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2017.02.028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28365527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer&amp;title=Imatinib%20Discontinuation%20in%20Chronic%20Myeloid%20Leukaemia%20Patients%20With%20Undetectable%20BCR%E2%80%90ABL%20Transcript%20Level:%20A%20Systematic%20Review%20and%20a%20Meta%E2%80%90Analysis&amp;author=L.%20Campiotti&amp;author=M.%20B.%20Suter&amp;author=L.%20Guasti&amp;volume=77&amp;publication_year=2017&amp;pages=48-56&amp;pmid=28365527&amp;doi=10.1016/j.ejca.2017.02.028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0019">
<span class="label">19.</span><cite>
Radich J. P., Hochhaus A., Masszi T., et al., “Treatment‐Free Remission Following Frontline Nilotinib in Patients With Chronic Phase Chronic Myeloid Leukemia: 5‐Year Update of the Enestfreedom Trial,” Leukemia
35, no. 5 (2021): 1344–1355, 10.1038/s41375-021-01205-5.
</cite> [<a href="https://doi.org/10.1038/s41375-021-01205-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8102196/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33707652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Treatment%E2%80%90Free%20Remission%20Following%20Frontline%20Nilotinib%20in%20Patients%20With%20Chronic%20Phase%20Chronic%20Myeloid%20Leukemia:%205%E2%80%90Year%20Update%20of%20the%20Enestfreedom%20Trial&amp;author=J.%20P.%20Radich&amp;author=A.%20Hochhaus&amp;author=T.%20Masszi&amp;volume=35&amp;issue=5&amp;publication_year=2021&amp;pages=1344-1355&amp;pmid=33707652&amp;doi=10.1038/s41375-021-01205-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0020">
<span class="label">20.</span><cite>
Hochhaus A., Baccarani M., Silver R. T., et al., “European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia,” Leukemia
34, no. 4 (2020): 966–984, 10.1038/s41375-020-0776-2.
</cite> [<a href="https://doi.org/10.1038/s41375-020-0776-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7214240/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32127639/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=European%20LeukemiaNet%202020%20Recommendations%20for%20Treating%20Chronic%20Myeloid%20Leukemia&amp;author=A.%20Hochhaus&amp;author=M.%20Baccarani&amp;author=R.%20T.%20Silver&amp;volume=34&amp;issue=4&amp;publication_year=2020&amp;pages=966-984&amp;pmid=32127639&amp;doi=10.1038/s41375-020-0776-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0021">
<span class="label">21.</span><cite>
Kantarjian H. M., Hughes T. P., Larson R. A., et al., “Long‐Term Outcomes With Frontline Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Enestnd 10‐year Analysis,” Leukemia
35, no. 2 (2021): 440–453, 10.1038/s41375-020-01111-2.
</cite> [<a href="https://doi.org/10.1038/s41375-020-01111-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7862065/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33414482/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Long%E2%80%90Term%20Outcomes%20With%20Frontline%20Nilotinib%20Versus%20Imatinib%20in%20Newly%20Diagnosed%20Chronic%20Myeloid%20Leukemia%20in%20Chronic%20Phase:%20Enestnd%2010%E2%80%90year%20Analysis&amp;author=H.%20M.%20Kantarjian&amp;author=T.%20P.%20Hughes&amp;author=R.%20A.%20Larson&amp;volume=35&amp;issue=2&amp;publication_year=2021&amp;pages=440-453&amp;pmid=33414482&amp;doi=10.1038/s41375-020-01111-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0022">
<span class="label">22.</span><cite>
le Coutre P., Ottmann O. G., Giles F., et al., “Nilotinib (Formerly AMN107), a Highly Selective BCR‐ABL Tyrosine Kinase Inhibitor, Is Active in Patients With Imatinib‐Resistant or ‐Intolerant Accelerated‐Phase Chronic Myelogenous Leukemia,” Blood
111, no. 4 (2008): 1834–1839, 10.1182/blood-2007-04-083196.
</cite> [<a href="https://doi.org/10.1182/blood-2007-04-083196" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18048643/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Nilotinib%20(Formerly%20AMN107),%20a%20Highly%20Selective%20BCR%E2%80%90ABL%20Tyrosine%20Kinase%20Inhibitor,%20Is%20Active%20in%20Patients%20With%20Imatinib%E2%80%90Resistant%20or%20%E2%80%90Intolerant%20Accelerated%E2%80%90Phase%20Chronic%20Myelogenous%20Leukemia&amp;author=P.%20le%20Coutre&amp;author=O.%20G.%20Ottmann&amp;author=F.%20Giles&amp;volume=111&amp;issue=4&amp;publication_year=2008&amp;pages=1834-1839&amp;pmid=18048643&amp;doi=10.1182/blood-2007-04-083196&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0023">
<span class="label">23.</span><cite>
Novartis
. Tasigna Summary of Product Characteristics, (2012). Accessed, April 29, 2024, <a href="https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/documents/product‐information/tasigna‐epar‐product‐information_en.pdf</a>.</cite>
</li>
<li id="hon70126-bib-0024">
<span class="label">24.</span><cite>
Stagno F., Abruzzese E., Iurlo A., et al., “Treatment‐Free Remission Outcome in Patients With Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib de‐escalation: 96‐Week Update of DANTE Study,” supplement, Blood
140, no. S1 (2022): 9614–9616, 10.1182/blood-2022-157700.</cite> [<a href="https://doi.org/10.1182/blood-2022-157700" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Treatment%E2%80%90Free%20Remission%20Outcome%20in%20Patients%20With%20Chronic%20Myeloid%20Leukemia%20in%20Chronic%20Phase%20Following%20One%20Year%20of%20Nilotinib%20de%E2%80%90escalation:%2096%E2%80%90Week%20Update%20of%20DANTE%20Study&amp;author=F.%20Stagno&amp;author=E.%20Abruzzese&amp;author=A.%20Iurlo&amp;volume=140&amp;issue=S1&amp;publication_year=2022&amp;pages=9614-9616&amp;doi=10.1182/blood-2022-157700&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0025">
<span class="label">25.</span><cite>
Mahon F.‐X., Richter J., Guilhot J., et al., “Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients With Deep Molecular Response: Results of the Euro‐Ski Trial,” Blood
128, no. 22 (2016): 787, 10.1182/blood.v128.22.787.787.</cite> [<a href="https://doi.org/10.1182/blood.v128.22.787.787" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Cessation%20of%20Tyrosine%20Kinase%20Inhibitors%20Treatment%20in%20Chronic%20Myeloid%20Leukemia%20Patients%20With%20Deep%20Molecular%20Response:%20Results%20of%20the%20Euro%E2%80%90Ski%20Trial&amp;author=F.%E2%80%90X.%20Mahon&amp;author=J.%20Richter&amp;author=J.%20Guilhot&amp;volume=128&amp;issue=22&amp;publication_year=2016&amp;pages=787&amp;doi=10.1182/blood.v128.22.787.787&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0026">
<span class="label">26.</span><cite>
Saussele S., Richter J., Guilhot J., et al., “Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (EURO‐SKI): A Prespecified Interim Analysis of a Prospective, Multicentre, Non‐Randomised, Trial,” Lancet Oncology
19, no. 6 (2018): 747–757, 10.1016/s1470-2045(18)30192-x.
</cite> [<a href="https://doi.org/10.1016/s1470-2045(18)30192-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29735299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncology&amp;title=Discontinuation%20of%20Tyrosine%20Kinase%20Inhibitor%20Therapy%20in%20Chronic%20Myeloid%20Leukaemia%20(EURO%E2%80%90SKI):%20A%20Prespecified%20Interim%20Analysis%20of%20a%20Prospective,%20Multicentre,%20Non%E2%80%90Randomised,%20Trial&amp;author=S.%20Saussele&amp;author=J.%20Richter&amp;author=J.%20Guilhot&amp;volume=19&amp;issue=6&amp;publication_year=2018&amp;pages=747-757&amp;pmid=29735299&amp;doi=10.1016/s1470-2045(18)30192-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0027">
<span class="label">27.</span><cite>
Boquimpani C. M., Szczudlo T., Mendelson E., Benjamin K., and Masszi T., “Attitudes and Perceptions of Patients (Pts) With Chronic Myeloid Leukemia in Chronic Phase (CML‐CP) Toward Treatment‐Free Remission (TFR),” Blood
124, no. 21 (2014): 4547, 10.1182/blood.v124.21.4547.4547.</cite> [<a href="https://doi.org/10.1182/blood.v124.21.4547.4547" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Attitudes%20and%20Perceptions%20of%20Patients%20(Pts)%20With%20Chronic%20Myeloid%20Leukemia%20in%20Chronic%20Phase%20(CML%E2%80%90CP)%20Toward%20Treatment%E2%80%90Free%20Remission%20(TFR)&amp;author=C.%20M.%20Boquimpani&amp;author=T.%20Szczudlo&amp;author=E.%20Mendelson&amp;author=K.%20Benjamin&amp;author=T.%20Masszi&amp;volume=124&amp;issue=21&amp;publication_year=2014&amp;pages=4547&amp;doi=10.1182/blood.v124.21.4547.4547&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0028">
<span class="label">28.</span><cite>
Žáčková D., Semerád L., Faber E., et al., “Why are Not all Eligible Chronic Myeloid Leukemia Patients Willing to Attempt Tyrosine Kinase Inhibitor Discontinuation? A Czech Nationwide Analysis Related to the TKI Stopping Trial HALF,” Leukemia
38, no. 4 (2024): 893–897.
</cite> [<a href="https://doi.org/10.1038/s41375-024-02215-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10997522/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38472478/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Why%20are%20Not%20all%20Eligible%20Chronic%20Myeloid%20Leukemia%20Patients%20Willing%20to%20Attempt%20Tyrosine%20Kinase%20Inhibitor%20Discontinuation?%20A%20Czech%20Nationwide%20Analysis%20Related%20to%20the%20TKI%20Stopping%20Trial%20HALF&amp;author=D.%20%C5%BD%C3%A1%C4%8Dkov%C3%A1&amp;author=L.%20Semer%C3%A1d&amp;author=E.%20Faber&amp;volume=38&amp;issue=4&amp;publication_year=2024&amp;pages=893-897&amp;pmid=38472478&amp;doi=10.1038/s41375-024-02215-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0029">
<span class="label">29.</span><cite>
Sharf G., Marin C., Bradley J. A., et al., “Treatment‐Free Remission in Chronic Myeloid Leukemia: The Patient Perspective and Areas of Unmet Needs,” Leukemia
34, no. 8 (2020): 2102–2112, 10.1038/s41375-020-0867-0.
</cite> [<a href="https://doi.org/10.1038/s41375-020-0867-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7387306/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32457354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Treatment%E2%80%90Free%20Remission%20in%20Chronic%20Myeloid%20Leukemia:%20The%20Patient%20Perspective%20and%20Areas%20of%20Unmet%20Needs&amp;author=G.%20Sharf&amp;author=C.%20Marin&amp;author=J.%20A.%20Bradley&amp;volume=34&amp;issue=8&amp;publication_year=2020&amp;pages=2102-2112&amp;pmid=32457354&amp;doi=10.1038/s41375-020-0867-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0030">
<span class="label">30.</span><cite>
Cayssials E., Torregrosa‐Diaz J., Gallego‐Hernanz P., et al., “Low‐Dose Tyrosine Kinase Inhibitors Before Treatment Discontinuation do Not Impair Treatment‐free Remission in Chronic Myeloid Leukemia Patients: Results of a Retrospective Study,” Cancer
126, no. 15 (2020): 3438–3447, 10.1002/cncr.32940.
</cite> [<a href="https://doi.org/10.1002/cncr.32940" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32459375/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Low%E2%80%90Dose%20Tyrosine%20Kinase%20Inhibitors%20Before%20Treatment%20Discontinuation%20do%20Not%20Impair%20Treatment%E2%80%90free%20Remission%20in%20Chronic%20Myeloid%20Leukemia%20Patients:%20Results%20of%20a%20Retrospective%20Study&amp;author=E.%20Cayssials&amp;author=J.%20Torregrosa%E2%80%90Diaz&amp;author=P.%20Gallego%E2%80%90Hernanz&amp;volume=126&amp;issue=15&amp;publication_year=2020&amp;pages=3438-3447&amp;pmid=32459375&amp;doi=10.1002/cncr.32940&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0031">
<span class="label">31.</span><cite>
Iurlo A., Cattaneo D., Malato A., et al., “Low‐Dose Ponatinib Is a Good Option in Chronic Myeloid Leukemia Patients Intolerant to Previous TKIs,” American Journal of Hematology
95, no. 10 (2020): E260–E263, 10.1002/ajh.25908.
</cite> [<a href="https://doi.org/10.1002/ajh.25908" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32557788/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Hematology&amp;title=Low%E2%80%90Dose%20Ponatinib%20Is%20a%20Good%20Option%20in%20Chronic%20Myeloid%20Leukemia%20Patients%20Intolerant%20to%20Previous%20TKIs&amp;author=A.%20Iurlo&amp;author=D.%20Cattaneo&amp;author=A.%20Malato&amp;volume=95&amp;issue=10&amp;publication_year=2020&amp;pages=E260-E263&amp;pmid=32557788&amp;doi=10.1002/ajh.25908&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0032">
<span class="label">32.</span><cite>
Iurlo A., Cattaneo D., Consonni D., et al., “Treatment Discontinuation Following Low‐Dose TKIs in 248 Chronic Myeloid Leukemia Patients: Updated Results From a Campus CML real‐life Study,” Frontiers in Pharmacology
14 (2023): 1154377, 10.3389/fphar.2023.1154377.
</cite> [<a href="https://doi.org/10.3389/fphar.2023.1154377" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10076530/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37033642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Pharmacology&amp;title=Treatment%20Discontinuation%20Following%20Low%E2%80%90Dose%20TKIs%20in%20248%20Chronic%20Myeloid%20Leukemia%20Patients:%20Updated%20Results%20From%20a%20Campus%20CML%20real%E2%80%90life%20Study&amp;author=A.%20Iurlo&amp;author=D.%20Cattaneo&amp;author=D.%20Consonni&amp;volume=14&amp;publication_year=2023&amp;pages=1154377&amp;pmid=37033642&amp;doi=10.3389/fphar.2023.1154377&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0033">
<span class="label">33.</span><cite>
Dulucq S., Rigal‐Huguet F., Nicolini F. E., et al., “EP751. Efficacy and Safety of Nilotinib in Chronic Myeloid Leukaemia Patients Who Failed to Achieve a Treatment‐free Remission Period After Imatinib Discontinuation: Results of the French NILO POST‐STIM Study. 25th Congress of the European Hematology Association Virtual Edition, 2020,” supplement, HemaSphere
4, no. S1 (2020): 333–334.</cite> [<a href="https://doi.org/10.1111/bjh.18796" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37004981/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=HemaSphere&amp;title=EP751.%20Efficacy%20and%20Safety%20of%20Nilotinib%20in%20Chronic%20Myeloid%20Leukaemia%20Patients%20Who%20Failed%20to%20Achieve%20a%20Treatment%E2%80%90free%20Remission%20Period%20After%20Imatinib%20Discontinuation:%20Results%20of%20the%20French%20NILO%20POST%E2%80%90STIM%20Study.%2025th%20Congress%20of%20the%20European%20Hematology%20Association%20Virtual%20Edition,%202020&amp;author=S.%20Dulucq&amp;author=F.%20Rigal%E2%80%90Huguet&amp;author=F.%20E.%20Nicolini&amp;volume=4&amp;issue=S1&amp;publication_year=2020&amp;pages=333-334&amp;pmid=37004981&amp;doi=10.1111/bjh.18796&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0034">
<span class="label">34.</span><cite>
Legros L., Nicolini F. E., Etienne G., et al., “The TKI‐Free Duration After a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI‐Free Remission After a Second Attempt,” supplement, Blood
134, no. S1 (2019): 28, 10.1182/blood-2019-123719.</cite> [<a href="https://doi.org/10.1182/blood-2019-123719" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20TKI%E2%80%90Free%20Duration%20After%20a%20First%20Discontinuation%20Attempt%20That%20Failed%20in%20CP%20CML%20Patients%20Is%20a%20Predictive%20Factor%20of%20TKI%E2%80%90Free%20Remission%20After%20a%20Second%20Attempt&amp;author=L.%20Legros&amp;author=F.%20E.%20Nicolini&amp;author=G.%20Etienne&amp;volume=134&amp;issue=S1&amp;publication_year=2019&amp;pages=28&amp;doi=10.1182/blood-2019-123719&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0035">
<span class="label">35.</span><cite>
Kim D. D. H., Busque L., Forrest D. L., et al., “Second Attempt of TKI Discontinuation With Dasatinib for Treatment‐Free Remission After Failing First Attempt With Imatinib: Treatment‐Free Remission Accomplished by Dasatinib (TRAD) Trial,” supplement, Blood
132, no. S1 (2018): 787, 10.1182/blood-2018-99-114656.</cite> [<a href="https://doi.org/10.1182/blood-2018-99-114656" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37697469/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Second%20Attempt%20of%20TKI%20Discontinuation%20With%20Dasatinib%20for%20Treatment%E2%80%90Free%20Remission%20After%20Failing%20First%20Attempt%20With%20Imatinib:%20Treatment%E2%80%90Free%20Remission%20Accomplished%20by%20Dasatinib%20(TRAD)%20Trial&amp;author=D.%20D.%20H.%20Kim&amp;author=L.%20Busque&amp;author=D.%20L.%20Forrest&amp;volume=132&amp;issue=S1&amp;publication_year=2018&amp;pages=787&amp;pmid=37697469&amp;doi=10.1182/blood-2018-99-114656&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70126-bib-0036">
<span class="label">36.</span><cite>
Hochhaus A., Boquimpani C., Rea D., et al., “Efficacy and Safety Results From ASCEMBL, a Multicenter, Open‐Label, Phase 3 Study of Asciminib, a First‐in‐Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) With Chronic Myeloid Leukemia in Chronic Phase (CML‐CP) Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors (TKIs),” supplement, Blood
136, no. S2 (2020): LBA‐4, 10.1182/blood-2020-143816.</cite> [<a href="https://doi.org/10.1182/blood-2020-143816" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Efficacy%20and%20Safety%20Results%20From%20ASCEMBL,%20a%20Multicenter,%20Open%E2%80%90Label,%20Phase%203%20Study%20of%20Asciminib,%20a%20First%E2%80%90in%E2%80%90Class%20STAMP%20Inhibitor,%20vs%20Bosutinib%20(BOS)%20in%20Patients%20(Pts)%20With%20Chronic%20Myeloid%20Leukemia%20in%20Chronic%20Phase%20(CML%E2%80%90CP)%20Previously%20Treated%20With%20%E2%89%A5%202%20Tyrosine%20Kinase%20Inhibitors%20(TKIs)&amp;author=A.%20Hochhaus&amp;author=C.%20Boquimpani&amp;author=D.%20Rea&amp;volume=136&amp;issue=S2&amp;publication_year=2020&amp;pages=LBA%E2%80%904&amp;doi=10.1182/blood-2020-143816&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>
Supporting Information S1
</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12333328/bin/HON-43-e70126-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70126-s001.pdf</a><sup> (152.3KB, pdf) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Deidentified data that support the findings of this study can be made available on request to the corresponding author, Alessandra Iurlo (<span>alessandra.iurlo@policlinico.mi.it</span>).</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Hematological Oncology are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/hon.70126"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/HON-43-e70126.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (969.4 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12333328/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12333328/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12333328%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333328/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12333328/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12333328/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40778574/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12333328/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40778574/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12333328/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12333328/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="HtT2E50sZMOaeJ8Ap5OCOfNeazQ7U8qUHfsoaSzurYFGAZVogbHpW5AnYBh4vhKv">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
